Skip to main content
ENSC
NASDAQ Life Sciences

Ensysce Proxy Supplement: Brokers Gain Discretionary Votes on Reverse Split; Staged Meeting Possible

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.366
Mkt Cap
$7.197M
52W Low
$0.23
52W High
$2.04
52W Position info
59% above low
Off High info
82% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ENSC sits 59% above its 52-week low of $0.23 on light trading volume (0.3× avg).

Summary

Ensysce supplemented its proxy to allow brokers to vote street-name shares on the reverse split without instructions and flagged a possible staged annual meeting, since Nasdaq requires a $4.00 bid price before the Series C conversion can close.


Key Events · Corporate Governance and Compliance · ENSC

  • Broker Discretion on Reverse Split

    The supplement reverses prior disclosure: brokers will have discretionary authority to vote street-name shares on Proposal 2 even without client instructions, raising the chance the reverse split passes.

  • Staged Meeting Possible

    Ensysce may vote the reverse split first and adjourn the December 14, 2026 annual meeting before the remaining proposals, then reconvene once Nasdaq initial listing requirements are met.

  • Nasdaq $4.00 Bid Price Condition

    Nasdaq treats approval of Proposal 1 (Series C conversion) as a change of control under Rules 5110(a) and 5635(b), so the company must satisfy a $4.00 minimum bid price before converting the preferred.

  • Delisting Deadline February 22, 2027

    The company remains below the $1.00 minimum bid price; Nasdaq extended the compliance deadline to February 22, 2027 and views a near-term reverse split as the only acceptable plan.


Analysis · ENSC · Life Sciences

The December 14 reverse-split vote just became easier to win. Brokers can now cast street-name shares on Proposal 2 without client instructions, materially lifting the odds of approval even if retail turnout is thin. The supplement also exposes a sequencing risk: because Nasdaq treats the Series C conversion as a change of control, the reverse split may have to be completed first to clear a $4.00 initial listing bid price, so the meeting could be adjourned and reconvened. Approval is framed as necessary to avoid delisting, with the bid-price deadline already extended to February 22, 2027.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENSC was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.23 to $2.04. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENSC - Latest Insights

ENSC
Nov 12, 2026, 11:18 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.380
Real-time Price: $0.366 info
Change: -$0.014 (-4%) info
Market Cap: $7.197M info
ENSC
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.366 info
Change: -$0.0211 (-5%) info
Market Cap: $7.197M info
ENSC
Nov 12, 2026, 4:17 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3871
Real-time Price: $0.366 info
Change: -$0.0211 (-5%) info
Market Cap: $7.197M info
ENSC
Nov 12, 2026, 4:15 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.3871
Real-time Price: $0.366 info
Change: -$0.0211 (-5%) info
Market Cap: $7.197M info
ENSC
Nov 04, 2026, 12:46 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3719
Real-time Price: $0.366 info
Change: -$0.0059 (-2%) info
Market Cap: $7.197M info